COVID-19 Clinical Trial
Official title:
A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Adjuvanted With Alum+CpG 1018) in Healthy Populations Aged 18 Years and Above in Indonesia
Verified date | February 2023 |
Source | PT Bio Farma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is an observer-blind, randomized, controlled prospective intervention study of Phase I. The primary objective is to evaluate the safety and immunogenicity of the SARS-CoV-2 protein subunit recombinant vaccine adjuvanted with Alum+CpG1018
Status | Completed |
Enrollment | 175 |
Est. completion date | January 24, 2023 |
Est. primary completion date | August 2, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Clinically healthy subjects aged 18 years and above. 2. Subjects have been informed properly regarding the study and signed the informed consent form. 3. Subjects will commit to comply with the instructions of the investigator and the schedule of the trial. Exclusion Criteria: 1. Subjects concomitantly enrolled or scheduled to be enrolled in another trial. 2. History of vaccination with any investigational product against COVID-19 (based on anamnesis) 3. Subjects who have history of COVID-19 (based on anamnesis or other examinations). 4. Evolving mild, moderate or severe illness, especially infectious disease or fever (body temperature =37.5?, measured with infrared thermometer/thermal gun). 5. The result of RT-PCR test for SARS-CoV-2 is positive. 6. Women who are lactating, pregnant or planning to become pregnant during the study period (judged by self-report of subjects and urine pregnancy test results). 7. Abnormality hematology and biochemical test results (for main study subset). 8. History of asthma, history of allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema. 9. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. 10. Patients with serious chronic diseases (serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc) which according to the investigator might interfere with the assessment of the trial objectives. 11. Subjects who have any history of confirmed or suspected immunosuppressive or immunodeficient state, or received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long-term corticosteroid therapy (> 2 weeks)). 12. Subjects who have history of uncontrolled epilepsy or other progressive neurological disorders, such as Guillain-Barre Syndrome. 13. Subjects receive any vaccination (other than COVID-19 vaccine) within 1 month before and after IP immunization. 14. Subjects plan to move from the study area before the end of study period. |
Country | Name | City | State |
---|---|---|---|
Indonesia | Fakultas Kedokteran Universitas Indonesia | Jakarta | Greater Jakarta |
Indonesia | Faculty of Medicine, Diponegoro University, Semarang | Semarang | Central Java |
Lead Sponsor | Collaborator |
---|---|
PT Bio Farma | Faculty of Medicine, Diponegoro University, Semarang, Fakultas Kedokteran Universitas Indonesia |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cellular immunity evaluation | Positive rate of specific T-cell response | 14 days after the last dose | |
Primary | Safety of the vaccine within 7 days after each dose | percentage of subjects with solicited and unsolicited Adverse Events (AE) | 7 days after each dose | |
Secondary | safety of the vaccine within 28 days after each dose | percentage of subjects with solicited and unsolicited AE | 28 days after each dose | |
Secondary | Serious Adverse Event (SAE) of the vaccine | percentage of subjects with at least 1 SAE | 6 months after the last dose | |
Secondary | Comparison of safety between vaccine and active control | percentage of subjects with AE and SAE between vaccine and active control group | 28 days after each dose and 6 months after the last dose | |
Secondary | Deviation of laboratory evaluation | Any deviation from routine laboratory evaluation that probably related to the dosing | 7 days after the first dose and 14 days after the last dose | |
Secondary | Inflammatory factor evaluation | The change of interleukin-6 (IL-6) in serum | 7 days after the first dose and 14 days after the last dose | |
Secondary | Immunogenicity profile after the last dose | GMT of IgG antibody and neutralization antibody | 14 days and 28 days after the last dose | |
Secondary | Immunogenicity profile after the last dose | seroconversion rate of IgG antibody and neutralization antibody | 14 days and 28 days after the last dose | |
Secondary | Comparison of immunogenicity profile | GMT of IgG antibody and neutralization antibody | 14 days and 28 days after the last dose | |
Secondary | Comparison of immunogenicity profile | seroconversion rate of IgG antibody and neutralization antibody | 14 days and 28 days after the last dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|